The limited outcome data on all testosterone-lowering agents make definitive treatment recommendations premature. In all, well-designed control studies are lacking, and more empirically-rigorous research is needed in this area. The use of antiandrogen medications to reduce sexual drive and consequently sexual behavior could be classified as a form of chemical restraint, a practice which is generally used to describe efforts to sedate or restrict freedoms of psychiatric patients.
Because of significant side effects, the prescription of such medications should be restricted to paraphilic patients and sexual offenders with at least a moderate or high risk for hands-on sexual offenses.
This reduction in sexual arousal is assumed to also reduce the motivation for sexually offending in individuals predisposed to such behaviors. Current Opinions in Psychiatry. Empirically established effective pharmacological treatments for mood disorders, ADHD, and impulsivity are well documented.
The limited outcome data on all testosterone-lowering agents make definitive treatment recommendations premature.
Neurology ; There was no history of earlier exposing or other inappropriate sexual behaviour with the daughter. Mar ; 31 2 : — Mulligan T, Siddiqi W. Be patient. Conquering the Confusion of Dementia Coding.
One solution would be to sentence all sexual offenders who meet certain criteria not only to prison, but to lifetime probation and enforced, lifetime treatment with Depo-Provera medroxyprogesterone acetate. Journal of Clinical Psychiatry.
Though much evidence exists demonstrating the efficacy of these treatments for other Axis I disorders, few empirical studies have examined the role of these interventions in the reduction of sexual arousal or sexual aggression. And in some jurisdictions or agencies, the off-label usage of pharmacological interventions is strongly discouraged.